Single nucleotide polymorphisms of the Peroxisome Proliferator-Activated Receptor-α gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: The STOP-NIDDM trial

Diabetes

Volumn 56, Issue 4, 2007, Pages 1181-1186

  Andrulionyte, Laura ^a   Kuulasmaa, Teemu ^a   Chiasson, Jean Louis ^b,c   Laakso, Markku ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PLACEBO;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENE FREQUENCY; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; DOUBLE-BLIND METHOD; FEMALE; GENOME; GLUCOSE INTOLERANCE; HUMANS; MALE; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; RNA, MESSENGER;

EID: 34047126320     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1110     Document Type: Article

References (25)

1. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPARalpha in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580, 2006
2. Vega RB, Huss JM, Kelly DP: The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868-1876, 2000
3. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferators-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes 50:411-417, 2001
4. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferators-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770-1778, 2003
5. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
6. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, Tremoli E: Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 148:397-406, 2000
7. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 30:871-878, 2000
8. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE: Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43:673-680, 2000
9. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA: A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 79:198-204, 2001
10. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE: Peroxisome proliferators-activated receptor α gene variation influences age of onset and progression of type 2 diabetes. Diabetes 54:582-586, 2005
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
12. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nat Genet 37:1217-1223, 2005
13. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P: A haplotype map of the human genome. Nature 437:1299-1320, 2005
14. Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M: Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med 84:701-708, 2006
15. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M: Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176-2184, 2004
16. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265, 2005
17. R Development Core Team. R: A Language and Environment for Statistical Computing [article online]. R Foundation for Statistical Computing, Vienna, Austria. Available from http://www.R-project.org. Accessed 20 May 2006
18. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres JP, Morgan K, Hudson TJ: Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinema. J Lipid Res 41:945-952, 2000
19. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B: Peroxisome proliferators-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55:1605-1613, 2006
20. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ: The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10:321-333, 2000
21. Gavin JR 3rd: Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 88:4H-8H, 2001
22. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M: PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66:562-573, 2005
23. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O: Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44:2220-2226, 2001
24. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80, 2000
25. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B: Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013-1028, 2002